Triple Agonist Reduces Hemoglobin A 1C and Weight in Patients With Type 2 Diabetes

The first-in-class glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 receptor (GLP-1), and glucagon triple hormone receptor retatrutide lowered hemoglobin A1C (HBA1c) levels and weight in patients with type 2 diabetes, according to topline results from a phase 3 clinical trial.